Overview
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).
Eligibility
Inclusion Criteria:
- Participants with BMI ≥ 27 kg/m² and established CVD
- History of at least one self-reported unsuccessful dietary effort to lose body weight
Exclusion Criteria:
- Known history of Type 1 diabetes mellitus
- Current or previous treatment with petrelintide or any other amylin analog


